As the use of biomarker testing options in the treatment of certain cancers continues to grow, so too do barriers to their use. Underpinning these barriers is a lack of understanding about how biomarker testing works and what impact it can have on selecting the most promising cancer treatment options.
Measurable residual disease (also known as “minimal residual disease”) refers to the number of cancer cells that remain during and after cancer treatment. Complete remission (less than 5% blasts in bone marrow) by morphologic assessment is not enough to accurately depict remaining malignant cells. MRD speaks to deeper levels of sensitivity to detect disease.
Monitoring a patient’s MRD at various points throughout active treatment and into remission provides important personalized insights into the effectiveness of a given therapy and may be used to predict which patients are at risk of relapse. Testing for MRD can shape treatment choices and overall patient management to achieve better outcomes. Unfortunately, routine MRD testing is variable, and there are currently no standards for optimal MRD testing.
Gain important and practical information for the assessment of measurable residual disease as part of routine clinical practice for patients with chronic lymphocytic leukemia (CLL). This presentation will be valuable for understanding the impact of MRD on treatment decisions and practice patterns, which has promise to lead to major improvements in outcomes for patients with CLL in the very near future.
MRD Clinical Updates in Chronic Lymphocytic Leukemia
Integration of MRD Testing: A Pathway for Patients with B-Cell Acute Lymphoblastic Leukemia
MRD Testing Implementation Roadmap
Navigate how to lay the groundwork for MRD testing, prepare your care team, implement testing, and evaluate ongoing progress.
MRD Testing Resource Library
Curated materials to help establish and implement MRD testing for your patients with adult B-cell ALL.